At 12.1% CAGR, Europe Botulinum Toxin Market is Projected to be Worth US$ 2,931.74 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the Europe botulinum toxin market was valued at US$ 1,174.94 million in 2023 and is expected to reach US$ 2,931.74 million by 2031, registering a CAGR of 12.1% from 2023 to 2031. Rising popularity of noninvasive aesthetics procedures and increasing use of botulinum toxin for enhancing facial aesthetics are among the critical factors attributed to drive the Europe botulinum toxin market growth.

Cosmetic surgery and injectable botulinum toxin are among the most popular noninvasive rejuvenation procedures. According to the ISAPS, in 2020, the botulinum toxin treatment was the leading noninvasive cosmetic procedure performed worldwide. Moreover, the use of botulinum toxin type A-based (BoNTA) cosmetic facial treatments are performed to improve the aesthetics of the upper and lower face. In the last decade, a facial rejuvenation procedure has gained significant popularity over different types of traditional surgeries. According to the ISAPS, ~7.3 million botulinum toxin procedures were performed globally in 2020. Thus, the surge in the adoption of botulinum toxin in facial aesthetic procedures for both men and women from all age groups is driving the botulinum toxin market growth.

On the contrary, side effects of botulinum toxin hamper the growth of Europe botulinum toxin market.

Based on product, the Europe botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held 94.5% share of Europe botulinum toxin market share in 2023, amassing US$ 1,109.89 million. It is projected to garner US$ 2,809.10 million by 2031 to register 12.3% CAGR during 2023–2031.

In terms of application, the Europe botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held 58.2% share of Europe botulinum toxin market in 2023, amassing US$ 684.15 million. It is anticipated to garner US$ 1,797.62 million by 2031 to expand at 12.8% CAGR during 2023–2031. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.

By end user, the Europe botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held 51.6% share of Europe botulinum toxin market in 2023, amassing US$ 606.83 million. It is projected to garner US$ 1,599.26 million by 2031 to expand at 12.9% CAGR from 2023 to 2031.

Based on country, the Europe botulinum toxin market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 31.2% share of Europe botulinum toxin market in 2023. It was assessed at US$ 364.94 million in 2023 and is likely to hit US$ 943.10 million by 2031, registering a CAGR of 12.6% during 2023–2031.

Key players operating in the Europe botulinum toxin market are Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Medytox Inc, and Galderma SA, among others.

• In August-2021, Merz Therapeutics has been granted the use of XEOMIN for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing 12 kg of chronic sialorrhea due to neurological / neurodevelopmental disorders on EU level. The national approvals of the country authorities involved will follow in the next weeks. The U.S. Food and Drug Administration approved in December 2020, and the Russian Federal Service for Surveillance in Healthcare in spring 2021. XEOMIN is first and only botulinum neurotoxin approved for this indication in Europe.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com